Jamp Pharma Corporation

What Jamp Pharma Corporation does

JAMP Pharma Corporation is a privately held Canadian pharmaceutical company founded in 1989 and headquartered in Boucherville, Quebec. The company manufactures and distributes generic prescription drugs, biosimilars, branded pharmaceuticals, natural health products, and hospital/acute-care injectables through six operating divisions: JAMP Pharma (generics), BioJAMP (biosimilars), Orimed Pharma (branded products), Wampole Group (natural health products and supplements), JAMP Acute Care & Injectables, and JAMP Pharma Manufacturing (domestic manufacturing). Its product portfolio spans more than 350 molecules and over 180 OTC supplements and beauty products, sold across Canada through wholesale distribution to community pharmacies and direct supply to hospitals.

The company's recent strategic activity is concentrated in therapeutic expansion: BioJAMP launched the biosimilars PrPexegra® (pegfilgrastim) and PrFilra® (filgrastim) in September 2025 for oncology supportive care, while Orimed Pharma introduced PrSolufy™, a liquid formulation of aripiprazole for psychiatric disorders. In March 2026, JAMP launched PrJAMP Enzalutamide, a generic alternative to Astellas's PrXtandi®, extending the oncology footprint. JAMP Care™, a patient support program, sits alongside the product portfolio as a post-sale adherence service.

JAMP generates revenue by selling pharmaceutical products through the Canadian pharmacy distribution network (one-time product sales to wholesalers, retail pharmacies, and hospitals). It does not publicly disclose pricing; its positioning centers on affordable generic alternatives and a reliable domestic supply manufactured in Quebec. Its market is exclusively Canada, with the workforce having more than tripled over the past five years to 350+ employees and 62 positions currently open.

Name

Jamp Pharma Corporation

Legal name

JAMP Pharma Corporation

Website

https://jamppharma.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

JAMP Pharma Corporation is a privately held Canadian pharmaceutical company headquartered in Boucherville, Quebec, that develops, manufactures, and distributes 350+ generic prescription drugs, biosimilars, branded pharmaceuticals, and OTC supplements to community pharmacies, hospitals, and consumers across Canada.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Generic pharmaceuticals
• Biosimilar drugs
• Oncology medications
• Natural health products
• Hospital injectables

Headquarters

HQ city

Boucherville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: Sale of generic prescription drugs through JAMP Pharma division, providing affordable alternatives to brand-name medications through pharmacy partnerships across Canada.
2. Biosimilar Products: Sale of biosimilar therapeutic options (PrPexegra®, PrFilra®) through BioJAMP division, offering cost-effective alternatives to reference biologics for cancer patients.
3. Branded Pharmaceuticals: Sale of branded pharmaceutical products through Orimed Pharma division, including psychiatric medications and specialty therapeutic areas.
4. Natural Health Products: Sale of over-the-counter supplements and beauty products through Wampole Group division.
5. Hospital/Acute Care Products: Sale of products administered in hospitals and healthcare facilities through JAMP Acute Care & Injectables division.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Jamp Pharma Corporation is a Canadian pharmaceutical manufacturer that develops, produces, and distributes generic prescription drugs, biosimilars, branded pharmaceuticals, natural health products, and hospital-administered injectables through six specialized divisions. The company operates domestic manufacturing in Boucherville, Quebec, and supplies over 350 molecules plus 180+ OTC supplements to Canadian pharmacies, hospitals, and healthcare facilities.

Product overview

JAMP Pharma Group operates as a diversified Canadian pharmaceutical company with six distinct divisions offering a comprehensive portfolio of healthcare products. The group provides generic medications through JAMP Pharma, biosimilar alternatives via BioJAMP, innovative branded products through Orimed Pharma, natural health products via Wampole Group, hospital-based injectables through JAMP Acute Care & Injectables, and domestically manufactured prescription drugs through JAMP Pharma Manufacturing. The portfolio encompasses over 350 molecules including prescription and over-the-counter medications, innovative products in diversified forms, and over 180 supplements and beauty products. Recent launches include PrPexegra® and PrFilra® (biosimilars for oncology support), PrSolufy™ (liquid formulation for psychiatric disorders), and PrJAMP Enzalutamide (generic oncology medication), all expanding treatment options and improving access to affordable care for Canadian patients.

Differentiator

Problem solved

Functional benefit

Brands

• JAMP Pharma: Generic pharmaceutical products division serving as pharmacy partners with focus on affordable medicines access.
• BioJAMP
• Orimed
• Wampole Group
• JAMP Acute Care & Injectables
• JAMP Pharma Manufacturing
• PrPexegra®
• PrFilra®
• PrSolufy™
• PrJAMP Enzalutamide

Products and services

• JAMP Pharma Generic Products

Quantifiable outcome

• Reducing infection incidence in cancer patients undergoing myelosuppressive chemotherapy through biosimilar filgrastim and pegfilgrastim products

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Pierre-Boucher Hospital FoundationminorOthers · 9 September 2025JAMP Pharma Group donated $75,000 to the Pierre-Boucher Hospital Foundation as part of the 'Avec vous pour la vie!' campaign, supporting organizations that improve access to care and patients' quality of life in Quebec.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Apotex Inc. Apotex is Canada's largest generic pharmaceutical manufacturer, producing a broad portfolio of affordable generic medicines. Directly comparable to JAMP as a Canadian-owned private generic manufacturer serving community pharmacies, hospitals, and export markets with vertically integrated manufacturing and distribution.
• Pharmascience Inc. Pharmascience is a major privately-held Canadian pharmaceutical company developing, manufacturing, and distributing generic and specialty pharmaceuticals. Closely comparable to JAMP as a Canadian private pharma with domestic manufacturing and broad therapeutic portfolio across multiple divisions.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic drug manufacturer with substantial Canadian operations. Comparable to JAMP as a generic pharmaceutical leader with global manufacturing scale, broad molecule portfolio, and established biosimilar franchise that competes head-to-head with JAMP's BioJAMP.
• Sandoz (Novartis): Sandoz is the global leader in generics and biosimilars, spun off from Novartis. Comparable to JAMP as a vertically integrated generics and biosimilars player with European manufacturing scale and established Canadian presence competing across JAMP's portfolio categories.
• Viatris Inc. Viatris (formed from Mylan-Upjohn merger) is a major global generics and specialty pharmaceutical company with significant Canadian operations. Comparable to JAMP for its broad generics portfolio, biosimilar development, and established pharmacy distribution channels in Canada.
• Pfizer Canada: Pfizer Canada is one of the largest pharmaceutical companies operating in Canada with branded and generic portfolios. Comparable to JAMP as a broad-portfolio pharma with hospital, retail pharmacy, and specialty distribution across Canada, though with much greater global scale.

Regional players

• Amgen Canada: Amgen Canada is the originator of Neulasta® (pegfilgrastim) and Neupogen® (filgrastim), the reference products for JAMP's newly launched biosimilars. Comparable to JAMP as the incumbent in the oncology-support biologics space where JAMP BioJAMP competes via biosimilar alternatives.
• Astellas Pharma Canada: Astellas Pharma Canada markets PrXtandi® (enzalutamide), the reference product for JAMP's newly launched PrJAMP Enzalutamide. Comparable to JAMP as the originator brand in the prostate cancer category where JAMP's generic competes on price.

Emerging players

• Celltrion Inc. Celltrion is a South Korean biosimilar specialist with leading global market share in filgrastim and pegfilgrastim biosimilars. Comparable to JAMP BioJAMP as a focused biosimilar developer entering the same Canadian oncology-support categories.

Others

• Bioventus Inc. Bioventus is an orthopedics-focused specialty pharma with biosimilars and branded products. Comparable to JAMP Orimed division for branded specialty therapeutics targeting Canadian healthcare providers, though in different therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCEDlOCBJpiZNoRBhLLk-OSw
• Facebookfacebook.com/GroupeJAMPPharma
• LinkedInlinkedin.com/company/jamp-pharma-corporation
• Instagraminstagram.com/groupejamppharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jamp Pharma Corporation